Literature DB >> 8393921

Presence of Epstein-Barr virus harbouring small and intermediate-sized cells in Hodgkin's disease. Is there a relationship with Reed-Sternberg cells?

N M Jiwa1, P Kanavaros, P C De Bruin, P van der Valk, A Horstman, W Vos, H Mullink, J M Walboomers, C J Meijer.   

Abstract

Forty-four cases of Hodgkin's disease (HD), mostly of the nodular sclerosing type, were investigated for the presence of Epstein-Barr virus (EBV) by polymerase chain reaction (PCR) and DNA and RNA in situ hybridization (DISH, RISH), as well as by immunohistochemistry for the detection of latent membrane protein-1 (LMP-1) of EBV. In situ hybridization (ISH) was combined with immunohistochemistry to correlate the presence and activity of the virus at the cellular level. In 18/34 (53 per cent) cases, EBV-DNA sequences could be detected with the PCR method. In 12/18 positive cases, DISH and RISH were also positive. In the remaining six EBV-PCR positive cases, two were also positive with RISH and LMP-1, whereas no positive signal with DISH could be obtained. All DISH and/or RISH positive cases were also positive for LMP-1. With RISH, not only the Reed-Sternberg cells and their mononuclear variants (RS cells) stained positive, but also small and intermediate cells frequently reacted with the EBV-specific probes (EBER-1 and -2). Double staining with cellular markers (CD3, CD20, CD45, CD45RO, CD68, and the lectin PNA) revealed that most of the smaller EBER-positive cells frequently did not express T, B, or histiocytic markers, but that they, as well as the RS cells, showed cytoplasmic and membranous staining with PNA. These smaller EBER-positive cells were not found in EBV-PCR negative HD. EBER-positive RS cells were almost always LMP-1 positive, as well as a substantial proportion of the intermediate-sized cells, whereas the majority of the small EBER-positive cells remained LMP-1 negative.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393921     DOI: 10.1002/path.1711700206

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders.

Authors:  A A Brink; C J Meijer; J M Nicholls; J M Middeldorp; A J van den Brule
Journal:  Mol Pathol       Date:  2001-04

2.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Authors:  A A Brink; D F Dukers; A J van den Brule; J J Oudejans; J M Middeldorp; C J Meijer; M Jiwa
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

3.  Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders.

Authors:  J J Oudejans; M Jiwa; A J van den Brule; F A Grässer; A Horstman; W Vos; P M Kluin; P van der Valk; J M Walboomers; C J Meijer
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

4.  Monitoring of epstein-barr virus DNA load in peripheral blood by quantitative competitive PCR.

Authors:  S J Stevens; M B Vervoort; A J van den Brule; P L Meenhorst; C J Meijer; J M Middeldorp
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype.

Authors:  D F Dukers; M H Vermeer; L H Jaspars; C A Sander; M J Flaig; W Vos; R Willemze; C J Meijer
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

6.  Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases.

Authors:  D P Hayes; A A Brink; M B Vervoort; J M Middeldorp; C J Meijer; A J van den Brule
Journal:  Mol Pathol       Date:  1999-04

7.  Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.

Authors:  J J Oudejans; D F Dukers; N M Jiwa; A J van den Brule; F A Grässer; P C de Bruin; A Horstman; W Vos; J van Gorp; J M Middeldorp; C J Meijer
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

8.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

9.  Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.

Authors:  Kostas Paschos; Paul Smith; Emma Anderton; Jaap M Middeldorp; Robert E White; Martin J Allday
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.